$MXCT News

MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance

MaxCyte Reports Preliminary Q3 Core Revenue Of ~$8.1M, Up 26% YoY; Raises FY26 Revenue Guidance To ~$34M, Core Business Revenue Outlook To ~$28M

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MaxCyte (MXCT) Q2 2026 Earnings Call Transcript

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

MaxCyte Launches CHANGE-seq-BE And ONE-seq-BE Off-Target Nomination Assays

MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ...

MaxCyte, Inc. Q2 2026 Earnings Call Summary

MaxCyte Q2 Earnings Call Highlights

MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call Transcript

MaxCyte Reports Second Quarter 2026 Financial Results

MaxCyte Affirms FY2026 Sales Guidance of $30.000M-$32.000M vs $31.082M Est

MaxCyte Q2 EPS $(0.08) Beats $(0.09) Estimate, Sales $7.271M Beat $6.475M Estimate

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

MaxCyte Enters Into Technology License Partnership With Genentech To Support Development Of Cell Therapy Programs

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering

Here’s Why MaxCyte (MXCT) is Becoming a High-Conviction Bet for Investors

MaxCyte Inc (MXCT) Q1 2026 Earnings Call Highlights: Revenue Meets Expectations Amid Core ...

MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript